European Journal of Clinical Pharmacology

, Volume 64, Issue 12, pp 1201–1208 | Cite as

Individualising netilmicin dosing in neonates

  • Catherine M. T. Sherwin
  • Roland S. Broadbent
  • Natalie J. Medlicott
  • David M. Reith
Pharmacokinetics and Disposition

Abstract

Purpose

The aim of this study was develop an optimal dosing regimen for netilmicin in neonates.

Methods

This was a population pharmacokinetic study in 97 neonates aged from 2 to 28 days after the due date who were being treated with netilmicin for suspected sepsis. The model was used to simulate dosing regimens.

Results

The principle factors influencing netilmicin clearance (CL) were postmenstrual age (PMA) and current body weight (CWT), and the principal determinant of volume of distribution (V) was CWT. The final covariate model was CL = 0.192 × (CWT/2)1.35 × (PMA/40)1.03, V = 1.5 × (CWT/2)0.3. The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates ≤27, 28–30, 31–33 and ≥34 weeks PMA, respectively.

Conclusion

Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT.

Keywords

Netilmicin Neonates Population pharmacokinetics Individualised dosing 

Notes

Acknowledgements

Dr. Nick H. G Holford, Associate Professor, Dept Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.

Catherine Sherwin is supported by a Freemasons Postgraduate Fellowship in Paediatrics and Child Health from the Freemasons of New Zealand.

References

  1. 1.
    Granati B, Assael BM, Chung M, Montini C, Parini R, Pollazzon P, Gagliardi L, Radwanski E, Rubaltelli FF (1985) Clinical pharmacology of netilmicin in preterm and term newborn infants. J Pediatr 106:664–669PubMedCrossRefGoogle Scholar
  2. 2.
    Herting RL, Lane AZ, Lorber RR, Wright JJ (1980) Netilmicin: chemical development and overview of clinical research. Scand J Infect Dis Suppl 23:20–29PubMedGoogle Scholar
  3. 3.
    Treluyer JM, Merle Y, Semlali A, Pons G (2000) Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. Clin Pharmacol Ther 67:600–609PubMedCrossRefGoogle Scholar
  4. 4.
    Michalsen H, Halvorsen K, Bergan T (1980) Netilmicin in the treatment of neonates with moderate and severe infections. Scand J Infect Dis Suppl 23:146–150PubMedGoogle Scholar
  5. 5.
    Begg EJ, Barclay ML (1995) Aminoglycosides - 50 years on. Br J Clin Pharmacol 39:597–603PubMedGoogle Scholar
  6. 6.
    Brooks JR, Marlow N, Reeves BC, Millar MR (2004) Use of once-daily netilmicin to treat infants with suspected sepsis in a neonatal intensive care unit. Biol Neonate 86:170–175PubMedCrossRefGoogle Scholar
  7. 7.
    Henriksson P, Svenningsen NW, Juhlin I, Haeger K (1980) Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics. Scand J Infect Dis Suppl 23:155–159PubMedGoogle Scholar
  8. 8.
    Berger A, Kretzer V, Gludovatz P, Rohrmeister K, Prusa AR, Kohlhauser C (2003) Evaluation of a netilmicin-loading dose in very low birthweight infants. Biol Neonate 83:25–29PubMedCrossRefGoogle Scholar
  9. 9.
    Gosden PE, Bedford KA, Dixon JJ, Speidel BD, Leaf AA, MacGowan AP (2001) Pharmacokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates. J Chemother 13:270–276PubMedGoogle Scholar
  10. 10.
    Bergan T, Michalsen H (1982) Pharmacokinetic assessment of netilmicin in newborns and older children. Infection 10:153–158PubMedCrossRefGoogle Scholar
  11. 11.
    Klingenberg C, Smabrekke L, Lier T, Flaegstad T (2004) Validation of a simplified netilmicin dosage regimen in infants. Scand J Infect Dis 36:474–479PubMedCrossRefGoogle Scholar
  12. 12.
    Davies MW, Cartwright DW (1998) Gentamicin dosage intervals in neonates: longer dosage interval - less toxicity. J Paediatr Child Health 34:577–580PubMedCrossRefGoogle Scholar
  13. 13.
    Mercado CK, Brodsky NL, McGuire MK, Hurt H (2004) Extended interval dosing of gentamicin in preterm infants. Am J Perinatol 21:73–77PubMedCrossRefGoogle Scholar
  14. 14.
    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JPA (2004) Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 114:111–118CrossRefGoogle Scholar
  15. 15.
    Begg EJ, Barclay ML, Duffull SB (1995) A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39:605–609PubMedGoogle Scholar
  16. 16.
    Bonate PL (2006) Pharmacokinetic-pharmacodynamic modeling and simulation. Springer, New YorkCrossRefGoogle Scholar
  17. 17.
    Ettlinger JJ, Bedford KA, Lovering AM, Reeves DS, Speidel BD, MacGowan AP (1996) Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. J Antimicrob Chemother 38:499–505PubMedCrossRefGoogle Scholar
  18. 18.
    Ohler KH, Menke JA, Fuller L (2000) Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit. Am Perinatol 17:285–290CrossRefGoogle Scholar
  19. 19.
    Giapros VI, Andronikou S, Cholevas VI, Papadopoulou ZL (1995) Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 9:163–166PubMedCrossRefGoogle Scholar
  20. 20.
    Langhendries JP, Battisti O, Bertrand JM, Francois A, Darimont J, Ibrahim S, Tulkens PM, Bernard A, Buchet JP, Scalais E (1993) Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 20:220–230PubMedGoogle Scholar
  21. 21.
    Arant BS (1978) Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 92:705–712PubMedCrossRefGoogle Scholar
  22. 22.
    Siegel JD, McCracken GH, Thomas ML, Threlkeld N (1979) Pharmacokinetic properties of netilmicin in newborn infants. Antimicrob Agents Chemother 15:246–253PubMedGoogle Scholar
  23. 23.
    Kuhn RJ, Nahata MC, Powell DA, Bickers RG (1986) Pharmacokinetics of netilmicin in premature-infants. Eur J Clin Pharmacol 29:635–637PubMedCrossRefGoogle Scholar
  24. 24.
    Bates DM, Watts DG (1988) Nonlinear regression analysis and its applications. Wiley, New YorkGoogle Scholar
  25. 25.
    Chuck SK, Raber SR, Rodvold KA, Areff D (2000) National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 30:433–439PubMedCrossRefGoogle Scholar
  26. 26.
    Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F (1991) Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther 50:55–65PubMedGoogle Scholar
  27. 27.
    Hayani KC, Hatzopoulos FK, Frank AL, Thummala MR, Hantsch MJ, Schatz BM, John EG, Vidyasagar D (1997) Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr 131:76–80PubMedCrossRefGoogle Scholar
  28. 28.
    Jauregizar N, Wald JA, Astobieta A, Sasiain JMR, Lukas JC, Calvo R (2003) Population pharmacokinetics of netilmicin in short-term prophylactic treatment. Br J Clin Pharmacol 55:552–559PubMedCrossRefGoogle Scholar
  29. 29.
    Darwish M, Batayneh M, Jenkins J, Scott M, Collier PS, McElnay JC (1992) Prediction of netilmicin disposition in neonates. Biopharm Drug Dispos 13:105–118PubMedCrossRefGoogle Scholar
  30. 30.
    Young TE, Mangum B (2002) In: Neofax. 15th edn. Acorn Publishing, Raleigh, North Carolina, pp 50–51Google Scholar
  31. 31.
    Rengelshausen J, Beedgen B, Tsamouranis K, Mikus G, Walter-Sack I, Haefeli WE, Linderkamp O (2006) Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol 62:773–777PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Catherine M. T. Sherwin
    • 1
  • Roland S. Broadbent
    • 1
  • Natalie J. Medlicott
    • 2
  • David M. Reith
    • 1
  1. 1.Department of Women’s and Child Health, Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand
  2. 2.School of PharmacyUniversity of OtagoDunedinNew Zealand

Personalised recommendations